Dasatinib, a novel Src/Abl inhibitor, could suppress the growth of HCC cells and enhance the anti-HCC efficacy of irinotecan by downregulation of PLK1 synthesis [32, 33]. The gene discussed is SRC; the disease is hepatocellular carcinoma.